See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Ying-Hong Shi
Zhongshan Hospital Fudan University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background : The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is ineffective making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis. Methods : In this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE. Results : A total of 230 patients (mean age 52.2±11.9 years; 172 men) were enrolled, and 46 (mean age 52.7±11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, γ-glutamyl transpeptidase (γ-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769-4.314, p <0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. After PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545-1.520, p =0.720) or DFS (HR: 3.345, 95% CI: 1.686-6.638, p =0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p =0.75; DFS: 11.2% vs 14.4%, respectively, p =0.06). Conclusions : The present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC.
Keywords
ombined hepatocellular carcinoma and intrahepatic cholangiocarcinoma; transarterial chemoembolization; overall survival; disease-free survival; propensity score matching analysis
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 02 Jul, 2020
Editorial decision: Accept
On 02 Jul, 2020
No comments provided
Submission checks complete
On 30 Jun, 2020
Editorial decision: Minor revision
On 30 Jun, 2020
No comments provided
Editorial decision: Minor revision
On 22 Jun, 2020
Review #2 received
Received 12 Jun, 2020
Review #1 received
Received 10 Jun, 2020
Reviewer #2 agreed
On 04 Jun, 2020
Reviewers invited
Invitations sent on 01 Jun, 2020
Reviewer #1 agreed
On 01 Jun, 2020
Editor assigned
On 25 May, 2020
Submission checks complete
On 24 May, 2020
Editor invited
On 24 May, 2020
Version 1
Posted 04 Mar, 2020
No comments provided
Editorial decision: Major revision
On 02 May, 2020
Reviewer #3 agreed
On 23 Apr, 2020
Review #2 received
Received 23 Apr, 2020
Reviewer #2 agreed
On 15 Apr, 2020
Review #1 received
Received 19 Mar, 2020
Reviewer #1 agreed
On 05 Mar, 2020
Reviewers invited
Invitations sent on 04 Mar, 2020
First submitted
On 23 Feb, 2020
Editor assigned
On 23 Feb, 2020
Submission checks complete
On 22 Feb, 2020
Editor invited
On 22 Feb, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Ying-Hong Shi
Zhongshan Hospital Fudan University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 02 Jul, 2020
Editorial decision: Accept
On 02 Jul, 2020
No comments provided
Submission checks complete
On 30 Jun, 2020
Editorial decision: Minor revision
On 30 Jun, 2020
No comments provided
Editorial decision: Minor revision
On 22 Jun, 2020
Review #2 received
Received 12 Jun, 2020
Review #1 received
Received 10 Jun, 2020
Reviewer #2 agreed
On 04 Jun, 2020
Reviewers invited
Invitations sent on 01 Jun, 2020
Reviewer #1 agreed
On 01 Jun, 2020
Editor assigned
On 25 May, 2020
Submission checks complete
On 24 May, 2020
Editor invited
On 24 May, 2020
Version 1
Posted 04 Mar, 2020
No comments provided
Editorial decision: Major revision
On 02 May, 2020
Reviewer #3 agreed
On 23 Apr, 2020
Review #2 received
Received 23 Apr, 2020
Reviewer #2 agreed
On 15 Apr, 2020
Review #1 received
Received 19 Mar, 2020
Reviewer #1 agreed
On 05 Mar, 2020
Reviewers invited
Invitations sent on 04 Mar, 2020
First submitted
On 23 Feb, 2020
Editor assigned
On 23 Feb, 2020
Submission checks complete
On 22 Feb, 2020
Editor invited
On 22 Feb, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background : The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is ineffective making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis. Methods : In this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE. Results : A total of 230 patients (mean age 52.2±11.9 years; 172 men) were enrolled, and 46 (mean age 52.7±11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, γ-glutamyl transpeptidase (γ-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769-4.314, p <0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. After PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545-1.520, p =0.720) or DFS (HR: 3.345, 95% CI: 1.686-6.638, p =0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p =0.75; DFS: 11.2% vs 14.4%, respectively, p =0.06). Conclusions : The present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC.
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...